Tags

Type your tag names separated by a space and hit enter

A prebiotic galactooligosaccharide mixture reduces severity of hyperpnoea-induced bronchoconstriction and markers of airway inflammation.
Br J Nutr. 2016 Sep; 116(5):798-804.BJ

Abstract

Gut microbes have a substantial influence on systemic immune function and allergic sensitisation. Manipulation of the gut microbiome through prebiotics may provide a potential strategy to influence the immunopathology of asthma. This study investigated the effects of prebiotic Bimuno-galactooligosaccharide (B-GOS) supplementation on hyperpnoea-induced bronchoconstriction (HIB), a surrogate for exercise-induced bronchoconstriction, and airway inflammation. A total of ten adults with asthma and HIB and eight controls without asthma were randomised to receive 5·5 g/d of either B-GOS or placebo for 3 weeks separated by a 2-week washout period. The peak fall in forced expiratory volume in 1 s (FEV1) following eucapnic voluntary hyperpnoea (EVH) defined HIB severity. Markers of airway inflammation were measured at baseline and after EVH. Pulmonary function remained unchanged in the control group. In the HIB group, the peak post-EVH fall in FEV1 at day 0 (-880 (sd 480) ml) was unchanged after placebo, but was attenuated by 40 % (-940 (sd 460) v. -570 (sd 310) ml, P=0·004) after B-GOS. In the HIB group, B-GOS reduced baseline chemokine CC ligand 17 (399 (sd 140) v. 323 (sd 144) pg/ml, P=0·005) and TNF-α (2·68 (sd 0·98) v. 2·18 (sd 0·59) pg/ml, P=0·040) and abolished the EVH-induced 29 % increase in TNF-α. Baseline C-reactive protein was reduced following B-GOS in HIB (2·46 (sd 1·14) v. 1·44 (sd 0·41) mg/l, P=0·015) and control (2·16 (sd 1·02) v. 1·47 (sd 0·33) mg/l, P=0·050) groups. Chemokine CC ligand 11 and fraction of exhaled nitric oxide remained unchanged. B-GOS supplementation attenuated airway hyper-responsiveness with concomitant reductions in markers of airway inflammation associated with HIB.

Authors+Show Affiliations

1Exercise and Health Research Group,Department of Sport Science,Sport, Health and Performance Enhancement (SHAPE) Research Centre,Nottingham Trent University,Nottingham NG11 8NS,UK.1Exercise and Health Research Group,Department of Sport Science,Sport, Health and Performance Enhancement (SHAPE) Research Centre,Nottingham Trent University,Nottingham NG11 8NS,UK.2Respiratory Research Unit,University of Nottingham,Nottingham NG5 1PB,UK.3Academic Department of Clinical Oncology,City Hospital Campus,University of Nottingham,Nottingham NG5 1PB,UK.4Clasado Research Services,Science and Technology Centre,Reading RG6 6UR,UK.1Exercise and Health Research Group,Department of Sport Science,Sport, Health and Performance Enhancement (SHAPE) Research Centre,Nottingham Trent University,Nottingham NG11 8NS,UK.1Exercise and Health Research Group,Department of Sport Science,Sport, Health and Performance Enhancement (SHAPE) Research Centre,Nottingham Trent University,Nottingham NG11 8NS,UK.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

27523186

Citation

Williams, Neil C., et al. "A Prebiotic Galactooligosaccharide Mixture Reduces Severity of Hyperpnoea-induced Bronchoconstriction and Markers of Airway Inflammation." The British Journal of Nutrition, vol. 116, no. 5, 2016, pp. 798-804.
Williams NC, Johnson MA, Shaw DE, et al. A prebiotic galactooligosaccharide mixture reduces severity of hyperpnoea-induced bronchoconstriction and markers of airway inflammation. Br J Nutr. 2016;116(5):798-804.
Williams, N. C., Johnson, M. A., Shaw, D. E., Spendlove, I., Vulevic, J., Sharpe, G. R., & Hunter, K. A. (2016). A prebiotic galactooligosaccharide mixture reduces severity of hyperpnoea-induced bronchoconstriction and markers of airway inflammation. The British Journal of Nutrition, 116(5), 798-804. https://doi.org/10.1017/S0007114516002762
Williams NC, et al. A Prebiotic Galactooligosaccharide Mixture Reduces Severity of Hyperpnoea-induced Bronchoconstriction and Markers of Airway Inflammation. Br J Nutr. 2016;116(5):798-804. PubMed PMID: 27523186.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A prebiotic galactooligosaccharide mixture reduces severity of hyperpnoea-induced bronchoconstriction and markers of airway inflammation. AU - Williams,Neil C, AU - Johnson,Michael A, AU - Shaw,Dominick E, AU - Spendlove,Ian, AU - Vulevic,Jelena, AU - Sharpe,Graham R, AU - Hunter,Kirsty A, PY - 2016/8/16/entrez PY - 2016/8/16/pubmed PY - 2017/5/17/medline KW - Airway inflammation KW - Asthma KW - B-GOS Bimuno-galactooligosaccharide KW - Bronchoconstriction KW - CCL11 chemokine CC ligand 11 KW - CCL17 chemokine CC ligand 17 KW - CRP C-reactive protein KW - EIB exercise-induced bronchoconstriction KW - EVH eucapnic voluntary hyperpnoea KW - FENO fraction of exhaled nitric oxide KW - FEV1 forced expiratory volume in 1 s KW - Gut microbiota KW - HIB hyperpnoea-induced bronchoconstriction KW - PEF peak expiratory flow KW - Prebiotics KW - TH2 T-helper 2 SP - 798 EP - 804 JF - The British journal of nutrition JO - Br. J. Nutr. VL - 116 IS - 5 N2 - Gut microbes have a substantial influence on systemic immune function and allergic sensitisation. Manipulation of the gut microbiome through prebiotics may provide a potential strategy to influence the immunopathology of asthma. This study investigated the effects of prebiotic Bimuno-galactooligosaccharide (B-GOS) supplementation on hyperpnoea-induced bronchoconstriction (HIB), a surrogate for exercise-induced bronchoconstriction, and airway inflammation. A total of ten adults with asthma and HIB and eight controls without asthma were randomised to receive 5·5 g/d of either B-GOS or placebo for 3 weeks separated by a 2-week washout period. The peak fall in forced expiratory volume in 1 s (FEV1) following eucapnic voluntary hyperpnoea (EVH) defined HIB severity. Markers of airway inflammation were measured at baseline and after EVH. Pulmonary function remained unchanged in the control group. In the HIB group, the peak post-EVH fall in FEV1 at day 0 (-880 (sd 480) ml) was unchanged after placebo, but was attenuated by 40 % (-940 (sd 460) v. -570 (sd 310) ml, P=0·004) after B-GOS. In the HIB group, B-GOS reduced baseline chemokine CC ligand 17 (399 (sd 140) v. 323 (sd 144) pg/ml, P=0·005) and TNF-α (2·68 (sd 0·98) v. 2·18 (sd 0·59) pg/ml, P=0·040) and abolished the EVH-induced 29 % increase in TNF-α. Baseline C-reactive protein was reduced following B-GOS in HIB (2·46 (sd 1·14) v. 1·44 (sd 0·41) mg/l, P=0·015) and control (2·16 (sd 1·02) v. 1·47 (sd 0·33) mg/l, P=0·050) groups. Chemokine CC ligand 11 and fraction of exhaled nitric oxide remained unchanged. B-GOS supplementation attenuated airway hyper-responsiveness with concomitant reductions in markers of airway inflammation associated with HIB. SN - 1475-2662 UR - https://www.unboundmedicine.com/medline/citation/27523186/A_prebiotic_galactooligosaccharide_mixture_reduces_severity_of_hyperpnoea_induced_bronchoconstriction_and_markers_of_airway_inflammation_ L2 - https://www.cambridge.org/core/product/identifier/S0007114516002762/type/journal_article DB - PRIME DP - Unbound Medicine ER -